Verastem, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Verastem, Inc. Verastem, Inc. (VSTM) is a late-stage biopharmaceutical company focused on developing and commercializing novel small molecule drugs targeting the RAS/MAPK signaling pathway in cancer, including RAF/MEK inhibition via avutometinib, FAK inhibition via defactinib, and KRAS G12D inhibition via VS-7375; the company advances these assets in monotherapy and combinations for low-grade serous ovarian cancer (LGSOC), pancreatic cancer, non-small cell lung cancer, colorectal cancer, and other RAS/MAPK-driven solid tumors, supported by investigator-sponsored trials and combinations with agents such as paclitaxel, pegylated liposomal doxorubicin, letrozole, anastrozole, and cetuximab. Founded in 2010 and headquartered in Needham, Massachusetts, Verastem operates primarily in the United States with a global development strategy through partnerships, employing approximately 78 people under CEO Daniel Paterson. In recent developments, the U.S. FDA approved the avutometinib plus defactinib combination (AVMAPKI FAKZYNJA) as the first therapy for adult patients with KRAS-mutant recurrent LGSOC, with commercialization underway following a planned mid-2025 launch; the company refinanced debt with Oberland Capital, entered a strategic commercialization partnership with IQVIA, completed a $75 million private placement, advanced the GenFleet Therapeutics collaboration with Phase 1/2 initiation of VS-7375 (GFH375) in July 2024 after Chinese IND approval in June 2024, and outlined 2025 priorities including RAMP trials and pipeline expansion.
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Verastem Oncology to Present at Jefferies Healthcare Conference
Verastem Oncology to Present at Jefferies Healthcare Conference
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
Cancer Stocks That Are Advancing the Future of Oncology Care
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Q1 Earnings Call Highlights
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates